JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

A

146.19

+0.72%↑

Search

Akebia Therapeutics Inc

Open

SectorGezondheidszorg

2.99 1.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.93

Max

3.03

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.9M

247K

Verkoop

5.1M

62M

Winstmarge

0.395

Werknemers

181

EBITDA

-6.1M

7.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+124.36% upside

Dividenden

By Dow Jones

Volgende Winsten

6 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-50M

838M

Vorige openingsprijs

1.98

Vorige sluitingsprijs

2.99

Nieuwssentiment

By Acuity

64%

36%

328 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Akebia Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 okt 2025, 22:47 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 okt 2025, 22:13 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 okt 2025, 21:20 UTC

Winsten

Correction to IBM 3Q Sales Jump Article

22 okt 2025, 20:57 UTC

Winsten

SAP Posts Higher 3Q Revenue, Operating Profit

22 okt 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 okt 2025, 23:46 UTC

Marktinformatie

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 okt 2025, 23:41 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:38 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:15 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 okt 2025, 22:28 UTC

Marktinformatie

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 okt 2025, 22:02 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 okt 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 okt 2025, 21:58 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 okt 2025, 21:57 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 okt 2025, 21:56 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 okt 2025, 21:47 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 okt 2025, 21:46 UTC

Acquisities, Fusies, Overnames

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 okt 2025, 21:28 UTC

Marktinformatie
Winsten

Correction to Alcoa Tariff Market Talk

22 okt 2025, 21:25 UTC

Winsten

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 okt 2025, 21:17 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 okt 2025, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

22 okt 2025, 20:59 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 20:51 UTC

Winsten

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 okt 2025, 20:44 UTC

Winsten

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Vergelijking

Prijswijziging

Akebia Therapeutics Inc Prognose

Koersdoel

By TipRanks

124.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7 USD  124.36%

Hoogste 8 USD

Laagste 6 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Akebia Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2.345 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

328 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat